This trial is testing a new drug, YL-13027, to see if it is safe and effective in patients with advanced solid tumors. The first part of the trial (phase Ia) is to determine the best dose of the drug (RP2D) by giving it to a small group of patients. The second part of the trial (phase II) is to expand the study to a larger group of patients to see if the drug has any preliminary anti-tumor activity.
1 Primary · 6 Secondary · Reporting Duration: Throughout the study for approximately 2 years
54 Total Participants · 1 Treatment Group
Primary Treatment: YL-13027 · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: